A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Brett Hughes, Alexander Guminski, Samantha Bowyer, Michael R. Migden, Chrysalyne D. Schmults, Nikhil I. Khushalani, Anne Lynn S. Chang, Jean‐Jacques Grob, Karl D. Lewis, George Ansstas, Fiona Day, Rahul Ladwa, B. Stein, Eva Muñoz‐Couselo, Friedegund Meier, Axel Hauschild, Dirk Schadendorf, Nicole Basset‐Séguin, Badri Modi, S. Dalac‐Rat, Lara Dunn, Lukas Flatz, Laurent Mortier, Sarah Guégan, Lucie Heinzerling, Janice M. Mehnert, Sabiha Trabelsi, Ainara Soria-Rivas, Alexander Stratigos, Claas Ulrich, Deborah Jean Lee Wong, M. Beylot‐Barry, Paolo Bossi, Cristina Bugés Sánchez, Sunandana Chandra, Caroline Robert, Jeffery S. Russell, Ann W. Silk, Jocelyn Booth, Suk‐Young Yoo, Frank Seebach, Israel Lowy, Matthew G. Fury, Danny Rischin